Sign In
to Vote &
Create Storyboards.
 
TherapeuticsMD, Inc. (NYSE MKT:TXMD) - Pharmacokinetic study presented in a poster session at The North American Menopause Society 2013 Annual Meeting in Dallas suggests that the first combination 17β-estradiol and progesterone capsule in clinical development may have overcome the well-recognized difficulties of achieving good bioavailability with oral administration of these hormones in combination. In a study of 66 healthy postmenopausal women, bioavailability of TX 12-001-HR, a capsule con...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard